An anti-Sema3A antibody has been patented to reduce immunosuppression caused by tumor-secreted Sema3A, and is available to the treatment of Alzheimer disease and immune dysfunction; Sema4D inhibitors are also patented to increase the frequency of tumor-infiltrating leukocytes by blocking the combination of Sema4D with its receptor (49), and is suitable for the treatment of human head and neck cancer, colon cancer, breast cancer, etc (50). Here, SEMA3A is linked to colonic neoplasm.